-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, J Immunother Cancer published a research result from the team of Professor Wu Xiaohua of Fudan University Affiliated Cancer Hospital, mainly to evaluate the PD-1 inhibitor camrelizumab combined with famitinib in the treatment of platinum resistance.
Efficacy of drug-relapsed ovarian cancer
.
Efficacy of drug-relapsed ovarian cancer
.
ovarian cancer
The study is an open-label, multicenter Phase II clinical study
.
Eligible patients with platinum-resistant ovarian cancer who received camrelizumab (200 mg intravenously every 3 weeks) and oral famitinib (20 mg once daily) were enrolled
The study is an open-label, multicenter Phase II clinical study
From April 19, 2019, to April 9, 2020, a total of 37 platinum-resistant patients received camrelizumab + famitinib
At the cutoff date of April 9, 2021, 9 (24.
Efficacy assessment
Efficacy assessmentMedian follow-up was 22.
0 months (range, 12.
0 - 23.
7), median progression-free survival (PFS) was 4.
1 months (95% CI, 2.
1 - 5.
7), and median OS was 18.
9 months (95% CI) , 10.
8 - not reached)
.
The OS rates at 6, 9, and 12 months were 89.
Median follow-up was 22.
PFS and OS
PFS and OSThe ORRs for primary platinum-resistant, secondary platinum-resistant, and primary platinum-refractory patients were 36.
4% (95% CI, 10.
9-69.
2), 13.
3% (95% CI, 1.
7-40.
5) and 27.
3% (95% CI, 6.
0-61.
0)
.
The DCRs were 72.
The ORRs for primary platinum-resistant, secondary platinum-resistant, and primary platinum-refractory patients were 36.
The ORR for PD-L1 CPS ≥1 and <1 patients was 50.
The most common grade 3 treatment-related adverse events were hypertension (32.
Adverse reactions
Adverse reactionsIn conclusion, the study showed that the combination of camrelizumab and famitinib showed antitumor activity in treated platinum-resistant patients with acceptable safety, which deserves further exploration
.
.
Studies have shown that the combination of camrelizumab and famitinib showed antitumor activity in previously treated platinum-resistant patients with acceptable safety, which deserves further exploration
Original source:
Xia L, Peng J, Lou G, Pan M, Zhou Q, Hu W, Shi H, Wang L, Gao Y, Zhu J, Zhang Y, Sun R, Zhou X, Wang Q, Wu X.
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
J Immunother Cancer.
2022 Jan;10(1):e003831.
doi: 10.
1136/jitc-2021-003831.
PMID: 35017154.
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
J Immunother Cancer.
2022 Jan;10(1):e003831.
doi: 10.
1136/jitc-2021-003831.
PMID: 35017154.
Leave a message here